At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC, discusses the immune response from STRIDE, a randomised, phase 2, open-label trial of sipuleucel-T with concurrent versus sequential enzalutamide administration in patients with metastatic castration-resistant prostate cancer.
STRIDE: Phase 2 study of sipuleucel-T in metastatic castration-resistant prostate cancer
10th July 2015
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?